Based on FDA feedback, Lannett Company (NYSE:LCI) expects to file its U.S. marketing application for biosimilar insulin glargine (Sanofi’s Lantus) in calendar year 2022.
https://seekingalpha.com/news/3582256-lannett-advances-insulin-glargine-biosimilar
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.